LMNGF - BioVaxys inks research pact for SARS-CoV-2 vaccine

BioVaxys ([[LMNGF]]) has entered into a research agreement with The Ohio State University, for development of its preclinical SARS-CoV-2 vaccine candidate, BVX-0320.Under the research collaboration, the company will evaluate the neutralizing antibodies generated against live SARS-CoV-2 virus by BVX-0320.Recently on October 14, BioVaxys's COVID-19 vaccine showed encouraging action in preclinical study.Additionally, BioVaxys's pipeline includes BVX-0918A, an IND-stage haptenized cancer cell vaccine for treating late stage ovarian cancer.

For further details see:

BioVaxys inks research pact for SARS-CoV-2 vaccine